Tag Archives: Professor Peter Humaidan

Merck announced the enrollment of first patient into new Phase III study in the area of fertility

• The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation • Study aims to recruit 946 patients across 17 European countries Darmstadt, Germany, 28-3-2014 — /EuropaWire/ — Merck, the global pharmaceutical and chemical company, … Read the full press release